IRIS
FERRARO, Giuseppa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.288
NA - Nord America 2.714
AS - Asia 1.350
SA - Sud America 360
Continente sconosciuto - Info sul continente non disponibili 67
AF - Africa 41
OC - Oceania 1
Totale 7.821
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.658
RU - Federazione Russa 1.755
SG - Singapore 535
CN - Cina 439
SE - Svezia 404
IE - Irlanda 353
BR - Brasile 310
DE - Germania 143
HK - Hong Kong 141
FR - Francia 130
IT - Italia 115
UA - Ucraina 101
PL - Polonia 73
GB - Regno Unito 70
FI - Finlandia 69
VN - Vietnam 62
IN - India 48
CA - Canada 24
BD - Bangladesh 21
AR - Argentina 19
BE - Belgio 18
AT - Austria 17
ZA - Sudafrica 16
MX - Messico 14
CO - Colombia 13
ID - Indonesia 13
TR - Turchia 13
IQ - Iraq 12
NL - Olanda 10
MA - Marocco 8
PK - Pakistan 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
JM - Giamaica 7
JP - Giappone 7
PH - Filippine 6
UZ - Uzbekistan 5
DZ - Algeria 4
EC - Ecuador 4
ES - Italia 4
ET - Etiopia 4
JO - Giordania 4
PE - Perù 4
VE - Venezuela 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
LT - Lituania 3
LV - Lettonia 3
RO - Romania 3
RS - Serbia 3
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CL - Cile 2
CR - Costa Rica 2
DK - Danimarca 2
IR - Iran 2
KE - Kenya 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TH - Thailandia 2
TN - Tunisia 2
AU - Australia 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.756
Salva come PNG Salva come JPEG
Città #
Moscow 461
Ashburn 396
Dublin 352
Singapore 319
Chandler 309
Dallas 241
Nyköping 205
Jacksonville 199
Beijing 159
Hong Kong 141
San Jose 125
The Dalles 87
New York 79
Council Bluffs 66
Warsaw 66
Ann Arbor 63
Los Angeles 63
Dearborn 58
Cambridge 51
Princeton 51
Medford 49
Lauterbourg 44
Des Moines 43
Messina 41
Munich 41
Boardman 34
Buffalo 30
Jinan 25
São Paulo 23
Woodbridge 22
Frankfurt am Main 21
Tianjin 21
Pune 19
Brussels 18
Ho Chi Minh City 18
San Mateo 17
Vienna 17
Lancaster 16
Shenyang 14
Turku 14
Belo Horizonte 13
Chicago 13
Wilmington 13
Guangzhou 12
Redondo Beach 12
Brooklyn 11
Nanjing 11
Orem 11
Hebei 10
Johannesburg 10
Montreal 10
Santa Clara 10
Zhengzhou 10
Chennai 9
Hanoi 9
Houston 9
Atlanta 8
Campinas 8
London 8
Manchester 8
Baghdad 7
Dong Ket 7
Mexico City 7
Rio de Janeiro 7
San Francisco 7
Shenzhen 7
Amsterdam 6
Da Nang 6
Denver 6
Goiânia 6
Grammichele 6
Jakarta 6
Mumbai 6
Ningbo 6
Shanghai 6
Taizhou 6
Ankara 5
Augusta 5
Brasília 5
Changsha 5
Columbus 5
Dhaka 5
Fort Washington 5
Helsinki 5
Joinville 5
Milan 5
Seattle 5
Stockholm 5
Tashkent 5
Tokyo 5
Washington 5
Addis Ababa 4
Boston 4
Curitiba 4
Dubai 4
Fuzhou 4
Haikou 4
Hillsboro 4
Lanzhou 4
Leawood 4
Totale 4.436
Salva come PNG Salva come JPEG
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 246
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 239
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 227
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 218
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 212
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 198
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 188
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 188
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 186
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 183
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 177
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 177
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 176
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 166
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 165
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 164
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 164
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 160
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 160
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 159
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 158
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 158
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 158
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 157
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 149
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 148
RANDOMISED PHASE II TERTIARY CHEMOPREVENTION TRIAL FOR COLORECTAL ADENOMA IN 24 PATIENTS WITH COLORECTAL CANCER TREATED WITH CELECOXIB 147
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 145
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 144
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 144
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 144
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 138
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient 136
Early Breast Cancer HER2 positivo in postmenopausa: strategia terapeutica adiuvante 135
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 134
NSCLC and HER2: between lights and shadows 134
Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity 129
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 128
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 127
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 120
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 116
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 116
Neoplasie della testa collo nell’ anziano 110
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 109
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 106
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 105
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 99
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 92
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 90
Invecchiamento e cancro. 85
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 63
null 52
null 37
null 33
null 22
Totale 7.821
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.738
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.738
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022410 0 66 10 11 14 6 23 9 5 99 57 110
2022/20231.137 87 118 49 105 83 104 18 88 444 2 29 10
2023/2024313 18 50 15 27 16 124 30 17 0 4 1 11
2024/20251.030 8 9 19 68 47 42 12 181 268 60 98 218
2025/20263.577 181 197 243 186 289 804 469 514 487 127 41 39
2026/2027122 36 86 0 0 0 0 0 0 0 0 0 0
Totale 7.821